Record Settlement Volume Driven by SPAC Litigation, While Settlement Values Fall Sharply

Delaware Chancery Court M&A litigation settlements rose to 25 in 2025, the highest count since 2012, but aggregate settlement value fell to $326.6 million from the 2023 inflation-adjusted peak of $734.8 million. The median settlement declined to a period low of $10 million, while the median settlement-to-transaction-value ratio fell to 0.5% from a 2020 high of 3.9%. De-SPAC cases accounted for 68% of settlements and helped depress values, although non-SPAC average settlements also declined to $19.4 million from $41.5 million in 2024.

Analysis

The investable read-through is modestly favorable for D&O underwriters, but frequency offsets severity: lower realized loss costs should benefit accident-year margins at carriers with meaningful public-company management-liability books, including AIG, CNA, WRB, ACGL, EG and AXS. The benefit will not appear immediately in reported earnings because claims-made reserves are released slowly and carriers may compete away the improvement through lower renewals. The more important 6-18 month question is whether elevated deal-related filing frequency persists after the SPAC litigation inventory burns down; if it does not, reserve releases could be followed by rate pressure rather than a durable underwriting upgrade.

For SPAC sponsors, directors and their insurers, smaller outcomes reduce tail-risk capital requirements and may marginally improve willingness to pursue combinations, but this is not enough to revive issuance absent a stronger IPO/M&A backdrop. The non-obvious negative is for plaintiff-side litigation economics and contingent-fee funding: lower recoveries combined with reduced fee awards make smaller fiduciary cases less financeable, potentially concentrating future challenges in large, conflicted transactions. That concentration raises event risk for acquirers undertaking transformative stock-funded deals, even if the average litigation burden is declining.

Consensus should avoid treating the data as evidence that Delaware governance risk has structurally disappeared. Settlement statistics are backward-looking, affected by case mix and claimed-damages assumptions, while a single large take-private, controller conflict, or appraisal-related judgment can reset severity expectations. No broad equity trade is warranted before insurers disclose reserve development, D&O pricing, and claims-frequency commentary in the next two earnings cycles.

Key Decisions for Investors

• Maintain a 1-3 month watchlist on AIG, CNA, WRB, ACGL, EG and AXS; upgrade only if 3Q/4Q disclosures show favorable D&O reserve development without renewed pricing deterioration. The key falsifier is management commentary indicating falling premiums or adverse development despite lower settlement severity.
• For merger-arbitrage books, apply a higher litigation-risk discount to large, stock-funded or controller-conflict transactions rather than reducing diligence across the board. Size any spread exposure assuming an idiosyncratic injunction or damages event can still delay closing by quarters.
• Avoid using this as a directional long in SPAC proxies or broad financial ETFs. Any benefit to sponsor economics is second-order and likely dominated by redemption rates, PIPE availability, IPO issuance, and target-company fundamentals.
• Monitor BUR as a potential negative read-through only if it reports lower realized yields, weaker case-originations, or increased concentration in large claims; absent those disclosures, the Delaware settlement sample is insufficient for a short recommendation.